Renal Cell Carcinoma | Current Treatment: Physician Insights | US | 2017
Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously treated metastatic renal cell carcinoma patients. This analysis provides insight on current use of approved therapies for renal cell carcinoma in the United States and on oncologists’ perception of these therapies.
Related Market Assessment Reports
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
